Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.18
<$0.01(1.03%)
At close: 4:00 PM EDT
$0.18
<$0.01(1.03%)
Day’s Range― - ―
52-Week Range$0.05 - $0.76
Previous Close$0.13
Volume406.85K
Average Volume (3M)686.32K
Market Cap
$4.33M
Enterprise Value-$3.08M
Total Cash (Recent Filing)$6.73M
Total Debt (Recent Filing)$410.05K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 17, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding60,603,740
10 Day Avg. Volume506,636
30 Day Avg. Volume686,321
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressionAdvancing into a second clinical cohort after safety review is a meaningful development milestone for ATR04-484. Continued enrollment can generate additional safety and early efficacy data, improving the program’s development prospects and supporting future partnering or regulatory discussions.
Balance Sheet RepairLow debt and a substantially improved debt-to-equity position give Azitra more financial flexibility than a highly leveraged development-stage biotech. The return to positive equity also indicates balance sheet repair, helping preserve capacity to fund clinical programs and corporate operations.
Listing Compliance RestoredRegaining NYSE American compliance removes an immediate structural listing obstacle and allows management to focus on advancing its clinical and cosmetic pipeline. Although enhanced monitoring remains for 12 months, restored status supports continued market access and corporate credibility.
Bears Say
Pre-revenue Operating ModelAzitra has not yet established recurring commercialization revenue, leaving its operating model dependent on clinical progress, financing, partnerships, or eventual product approval. Persistent multimillion-dollar losses indicate that meaningful operating leverage remains unproven over the next several quarters.
Heavy Cash BurnSustained negative operating and free cash flow requires Azitra to continually fund research, development, and corporate activities before products generate sales. This reduces financial resilience and makes future clinical execution increasingly dependent on access to external capital.
Equity Financing DilutionThe at-the-market program provides flexible funding for working capital and general corporate purposes, but issuing additional shares can dilute existing ownership. Reliance on equity financing also underscores that current operations and development programs are not yet self-funded by revenue.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.05 and its highest was $0.76 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $4.33M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on Aug 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.055.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Overvalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.02.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 60,603,740 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Technical Analysis
Ownership Overview
27.62% Insiders
0.47% Mutual Funds
69.91% Other Institutional Investors
1.99% Public Companies and
Individual Investors